

Omeros shares slide after mixed Q3 results—Yartemlea sales jump 26% sequentially, but revenue misses and EU setbacks weigh.
You can purchase shares of Omeros (NASDAQ:OMER) through any online brokerage.
Other companies in Omeros’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Omeros has a consensus price target of $25.67.
The stock price for Omeros (NASDAQ: OMER) is $14.54 last updated November 18, 2026 at 7:47 PM EST.
There are no upcoming dividends for Omeros.
Omeros does not have any upcoming earnings scheduled.
There is no upcoming split for Omeros.
Omeros is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases,...